Skip to main content
Explore URMC
menu

ILYM15080 / ZUMA-2 / Patrick Reagan

Research Question:
Is KTE-C19 safe and effective in treating your lymphoma when administered after a 3 day course of chemotherapy?

Basic Study Information

Purpose:
The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02601313?term=Kite+102&rank=1
Study Reference #: ILYM-15080

Lead Researcher (Principal Investigator)

Lead Researcher:  Patrick Reagan

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma, Mantle-Cell

More information about Mantle cell lymphoma

Return to Search